Home > Healthcare > Pharmaceuticals > Finished Drug Form > Oral Mucositis Treatment Market

Oral Mucositis Treatment Market Share

Report ID: GMI9273
Published Date: Apr 2024
Report Format: PDF

Download Free Sample

Oral Mucositis Treatment Market Share

The market encompasses a variety of therapies addressing the challenging symptoms of cancer treatment-induced mucositis. Continuous advancements in pharmaceutical R&D and innovative drug delivery systems propel market expansion, responding to the rising global cancer burden and the increasing focus on enhancing patients' quality of life during treatment. This growth fosters competition among industry leaders, shaping the landscape of oral mucositis therapeutics.

Oral Mucositis Treatment Market Companies

Prominent players operating in the oral mucositis treatment industry include:

Amgen Inc.
Basic Pharma Life Science Pvt Ltd.
CANbridge Pharmaceuticals Inc.
Enzychem Lifesciences Corporation
EpicentRx, Inc.
Galera Therapeutics, Inc.
Helsinn Healthcare SA.
Innovation Pharmaceuticals Inc.
Monopar Therapeutics, Inc.
Pfizer Inc.
Soleva Pharma, LLC.
Swedish Orphan Biovitrum AB

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The oral mucositis treatment market was valued at USD 1.6 billion in 2023 and is expected to exhibit growth at 7.1% CAGR from 2024 – 2032, attributed to the ongoing advancements in cancer therapy, increasing prevalence of cancer, and rising geriatric population

The anti-inflammatory segment accounted for 30% of the market share in 2023, owing to the innovations in anti-inflammatory therapies.

North America oral mucositis treatment market size generated USD 586.9 million in 2023 and is anticipated to grow at 6.8% CAGR between 2024 – 2032, driven by prevalence of cancers, including head and neck cancers, leukemia, and lymphomas.

Amgen Inc., Basic Pharma Life Science Pvt Ltd., CANbridge Pharmaceuticals Inc., Enzychem Lifesciences Corporation, EpicentRx, Inc., Galera Therapeutics, Inc., Helsinn Healthcare SA., Innovation Pharmaceuticals Inc., Monopar Therapeutics, Inc., Pfizer Inc., Soleva Pharma, LLC. and Swedish Orphan Biovitrum AB